Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
Conditions
Prostate CarcinomaSummary
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the diagnostic performance as quantified by the area under the ROC curve to detect aggressive prostate cancer.
II. To develop a risk prediction model by incorporating overall PI-RADS, PSA, Gleason score and clinical stage to predict the presence of aggressive prostate cancer.
SECONDARY OBJECTIVES:
I. To evaluate the diagnostic performance of the individual PI-RADS score of each MRI parameter (T2W, DWI and DCE), as determined by local imaging review.
TERTIARY OBJECTIVES:
I. All clinical data including magnetic resonance (MR) images will be banked for future exploratory research aims.
OUTLINE:
Patients undergo mpMRI within 3 months prior to schedule surgery.
After completion of study, patients are followed up until radical prostatectomy pathology is reported and finalized.
Locations
29 locations Found with status Recruiting
Status
- RECRUITING
Contact Person
- Site Public Contact
- 855-776-0015
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 352-273-8675
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 855-776-0015
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 317-278-5632
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 800-237-1225
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 913-588-3671
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 913-588-3671
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 504-210-3539
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 504-210-3539
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 313-916-3721
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 616-391-1230
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 313-916-3721
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 855-776-0015
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 314-251-7066
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 800-639-6918
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 212-746-1848
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 877-668-0683
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 717-531-3779
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 855-216-0098
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 215-728-4790
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 866-632-6789
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 214-648-7097
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 877-632-6789
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 877-632-6789
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 877-632-6789
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 877-469-5300
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 877-632-6789
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 304-293-7374
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Status
- RECRUITING
Contact Person
- Site Public Contact
- 262-928-5539
- [email protected]
Principal Investigator
- Clare Tempany-Afdhal
Eligibility Criteria
Inclusion Criteria:
* Recently diagnosed with prostate cancer for whom definitive surgical treatment is indicated
Exclusion Criteria:
* Not suitable to undergo MRI or receive gadolinium-based contrast agent (severe, untreatable claustrophobia; MRI-incompatible metallic objects or implanted medical devices; renal failure; weight greater than allowable by scanner per institutional standard practice)
* Prior surgical and/or non-surgical treatment for prostate cancer
* Prior hip replacement or other major pelvic surgery
Study Plan
Diagnostic (mpMRI)
EXPERIMENTAL
Patients undergo mpMRI within 3 months prior to schedule surgery.
DIAGNOSTIC_TEST:
Multiparametric Magnetic Resonance ImagingDescription:
Undergo mpMRI
Outcome Measures
Primary Outcome Measures
Diagnostic performance of overall prostate imaging reporting and data system (PI-RADS) score
Risk prediction model
Secondary Outcome Measures
Diagnostic performance of the individual prostate imaging reporting and data system (PI-RADS) score
Timeline
Last Updated
October 22, 2024Start Date
October 5, 2018Today
February 5, 2025Completion Date ( Estimated )
August 1, 2025
Sponsors of this trial
Lead Sponsor
ECOG-ACRIN Cancer Research GroupCollaborating Sponsors
National Cancer Institute (NCI)